Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Payables (2017 - 2025)

Protagonist Therapeutics' Payables history spans 9 years, with the latest figure at $28.3 million for Q4 2025.

  • For Q4 2025, Payables rose 19.31% year-over-year to $28.3 million; the TTM value through Dec 2025 reached $28.3 million, up 19.31%, while the annual FY2025 figure was $28.3 million, 19.31% up from the prior year.
  • Payables for Q4 2025 was $28.3 million at Protagonist Therapeutics, up from $5.6 million in the prior quarter.
  • Across five years, Payables topped out at $37.7 million in Q4 2021 and bottomed at $2.9 million in Q1 2025.
  • The 5-year median for Payables is $17.1 million (2021), against an average of $16.4 million.
  • The largest annual shift saw Payables soared 1126.54% in 2021 before it tumbled 90.35% in 2022.
  • A 5-year view of Payables shows it stood at $37.7 million in 2021, then crashed by 90.35% to $3.6 million in 2022, then surged by 431.81% to $19.4 million in 2023, then grew by 22.39% to $23.7 million in 2024, then increased by 19.31% to $28.3 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Payables are $28.3 million (Q4 2025), $5.6 million (Q3 2025), and $3.2 million (Q2 2025).